Form 4: Medifast CFO Maloney's Stock Transactions

Medifast's CFO, James P. Maloney, reported a series of stock transactions including restricted stock unit grants, performance stock unit vesting, and shares withheld for tax obligations.

Summary

• James P. Maloney, Chief Financial Officer of Medifast, Inc., reported changes in his beneficial ownership of common stock.
• On March 13, 2026, 918 shares were disposed of at $9.62 per share to cover tax withholding upon restricted stock unit vesting.
• On March 17, 2026, 482 shares were disposed of at $10.05 per share for tax withholding related to restricted stock unit vesting.
• On March 25, 2026, 3,224 shares were disposed of at $9.59 per share for tax withholding upon restricted stock unit vesting.
• On March 25, 2026, Mr. Maloney was granted 34,344 restricted stock units (RSUs) under the 2012 Share Incentive Plan, which will vest in three equal annual installments starting one year from the grant date.
• Also on March 25, 2026, 1,014 shares of common stock were issued upon the vesting and settlement of performance stock units (PSUs) previously granted on March 17, 2023, based on performance criteria certified on February 5, 2026.
• Following these transactions, Mr. Maloney's direct beneficial ownership of Medifast common stock is 73,033 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive due to the significant grant of new restricted stock units and the vesting of performance units, indicating continued executive incentive alignment and achievement of past performance goals, despite the routine tax-related dispositions.

Positives

• Grant of 34,344 restricted stock units (RSUs) to the CFO, aligning executive incentives with long-term company performance.
• Vesting of 1,014 performance stock units (PSUs) indicates achievement of previously set performance criteria.

Negatives

• Disposition of 4,624 shares in total (918, 482, 3,224) to cover tax withholding obligations, which is a standard practice but reduces direct share count.

Future Outlook

The 34,344 restricted stock units granted to the CFO will vest in three equal annual installments, beginning on the first anniversary of the March 25, 2026 grant date, indicating future share issuances tied to continued employment.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider trading activity, primarily related to executive compensation and planned stock transactions. These types of grants and vestings are common mechanisms for aligning executive incentives with shareholder interests and are standard practice across publicly traded companies.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) as part of executive compensation packages is a widely adopted practice across various industries, including the health and wellness sector where Medifast operates.
• Companies like Herbalife Nutrition (HLF) and WW International (WW) also frequently utilize equity awards to incentivize their leadership.
• The structure of vesting over multiple years for RSUs and tying PSUs to performance criteria aligns with best practices for long-term incentive plans, aiming to retain key talent and drive sustained company performance.

Stakeholder Impact

• Shareholders: The grant of new equity awards aligns the CFO's interests with long-term shareholder value creation. The vesting of PSUs indicates past performance targets were met, which could be positive for shareholder confidence.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• The 34,344 restricted stock units granted on March 25, 2026, will vest in three equal annual installments, with the first installment vesting on March 25, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including stock grants, vesting, and tax-related dispositions. While the grant of new equity awards is a positive for executive alignment, these transactions are expected and do not provide new fundamental information that would significantly alter the investment thesis for Medifast. Therefore, a "hold" recommendation is appropriate, as the filing does not present a compelling reason for a change in an investor's current position.

Keywords

Medifast, MED, Form 4, insider transaction, James P. Maloney, Chief Financial Officer, CFO, restricted stock units, RSU, performance stock units, PSU, stock grant, stock vesting, beneficial ownership, executive compensation